Literature DB >> 10579438

Salivary antibodies following parenteral immunization of infants with a meningococcal serogroup A and C conjugated vaccine.

R Borrow1, A J Fox, K Cartwright, N T Begg, D M Jones.   

Abstract

Bacterial and viral salivary antibody testing is proving sensitive and specific, useful for epidemiological studies, and is simple and non-invasive. Salivary serogroup C polysaccharide-specific (SC PS-S) IgA and IgG were determined as a proportion of total salivary IgA and IgG in a group of UK infants who were recipients of a conjugated A/C meningococcal PS vaccine. Geometric mean concentrations (GMCs) of salivary SC PS-S IgG per mg of total IgG (microg/mg) were 0.1 pre-vaccination, rising to 8.2 post first, 16.1 post second and 29.3 post third dose of vaccine. For IgA, the corresponding GMCs in ng/mg were 0.1, 82.8, 69.6 and 91.2. Significant correlations (P < 0.0001) were found between serum Ig and salivary IgG SC PS-S antibody for pre-vaccine and 1 month post each dose of vaccine suggesting that SC PS-S IgG in saliva was largely derived from serum. Of the five infants whose sera were analysed for isotype-specific responses, only traces of IgM and IgA were measurable suggesting that the SC PS-S IgA was locally produced. These findings suggests that the widespread use of meningococcal conjugate vaccines is likely to reduce nasopharyngeal carriage and may thereby induce herd immunity in the vaccinated population.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10579438      PMCID: PMC2810750          DOI: 10.1017/s0950268899002915

Source DB:  PubMed          Journal:  Epidemiol Infect        ISSN: 0950-2688            Impact factor:   2.451


  11 in total

1.  Meningococcal group C conjugate vaccines.

Authors:  J Maclennan
Journal:  Arch Dis Child       Date:  2001-05       Impact factor: 3.791

Review 2.  Mucosal immunology of vaccines against pathogenic nasopharyngeal bacteria.

Authors:  Q Zhang; A Finn
Journal:  J Clin Pathol       Date:  2004-10       Impact factor: 3.411

3.  Within-subject variability in repeated measures of salivary analytes in healthy adults.

Authors:  Mark V Thomas; Adam Branscum; Craig S Miller; Jeffrey Ebersole; Mohanad Al-Sabbagh; Julie L Schuster
Journal:  J Periodontol       Date:  2009-07       Impact factor: 6.993

4.  Primary and booster mucosal immune responses to meningococcal group A and C conjugate and polysaccharide vaccines administered to university students in the United Kingdom.

Authors:  Q Zhang; R Lakshman; R Burkinshaw; S Choo; J Everard; S Akhtar; A Finn
Journal:  Infect Immun       Date:  2001-07       Impact factor: 3.441

5.  A glycoconjugate vaccine for Neisseria meningitidis induces antibodies in human infants that afford protection against meningococcal bacteremia in a neonate rat challenge model.

Authors:  Kenneth T Mountzouros; Kelly A Belanger; Alan P Howell; Garvin S Bixler; Dace V Madore
Journal:  Infect Immun       Date:  2002-12       Impact factor: 3.441

6.  Comparison and correlation of neisseria meningitidis serogroup B immunologic assay results and human antibody responses following three doses of the Norwegian meningococcal outer membrane vesicle vaccine MenBvac.

Authors:  Jamie Findlow; Stephen Taylor; Audun Aase; Rachel Horton; Robert Heyderman; Jo Southern; Nick Andrews; Rita Barchha; Ewan Harrison; Ann Lowe; Emma Boxer; Charlotte Heaton; Paul Balmer; Ed Kaczmarski; Philipp Oster; Andrew Gorringe; Ray Borrow; Elizabeth Miller
Journal:  Infect Immun       Date:  2006-08       Impact factor: 3.441

7.  Immune responses to novel pneumococcal proteins pneumolysin, PspA, PsaA, and CbpA in adenoidal B cells from children.

Authors:  Qibo Zhang; Sharon Choo; Adam Finn
Journal:  Infect Immun       Date:  2002-10       Impact factor: 3.441

8.  Induction of salivary antibody levels in Dutch adolescents after immunization with monovalent meningococcal serogroup C or quadrivalent meningococcal serogroup A, C, W and Y conjugate vaccine.

Authors:  Mariëtte B van Ravenhorst; Gerco den Hartog; Fiona R M van der Klis; Debbie M van Rooijen; Elisabeth A M Sanders; Guy A M Berbers
Journal:  PLoS One       Date:  2018-04-19       Impact factor: 3.240

9.  Use of saliva to monitor meningococcal vaccine responses: proposing a threshold in saliva as surrogate of protection.

Authors:  Mariëtte B van Ravenhorst; Fiona R M van der Klis; Debbie M van Rooijen; Elisabeth A M Sanders; Guy A M Berbers
Journal:  BMC Med Res Methodol       Date:  2019-01-05       Impact factor: 4.615

10.  Characterization of humoral and cellular immune responses elicited by meningococcal carriage.

Authors:  K Robinson; K R Neal; C Howard; J Stockton; K Atkinson; E Scarth; J Moran; A Robins; I Todd; E Kaczmarski; S Gray; I Muscat; R Slack; D A A Ala'Aldeen
Journal:  Infect Immun       Date:  2002-03       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.